Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment

PharmacoEconomics

Volumn 11, Issue 4, 1997, Pages 367-376

  Badia, Xavier ^a   Segú, Josep Lluis ^a   Ollé, Ariadna ^a   Brosa, Max ^b   Monés, Joan ^c   Ponte, Lorenzo García ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SOIKOS   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d ABBOTT LABORATORIES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIULCER AGENT; CLARITHROMYCIN; OMEPRAZOLE;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DUODENUM ULCER; HELICOBACTER PYLORI; HUMAN; MODEL; PRIORITY JOURNAL; REINFECTION; RELAPSE; STOMACH ACID SECRETION;

EID: 0030974972     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711040-00008     Document Type: Article

References (43)

1. Beneyto F. Estudio epidemiológico de la mortalidad por úlcera gástrica y duodenal en España (1951-1979). Rev Esp Enferm Apar Dig 1987; 71: 481-7
2. Tytgat GNJ. Long-term consequences of Helicobacter pylori eradication. Scand J Gastroenterol 1994; 29 Suppl. 205: 38-44
3. Jönsson B. The social cost of peptic ulcer in Sweden. Scand J Gastroenterol 1980; 15 Suppl. 63: 181-9
4. Jönsson B, Drummond MF, Stålhammar N-O. Cost-effectiveness of omeprazole and ranitidine in the treatment of duodenal ulcer. Pharmacoeconomics 1994; 5 Suppl. 3: 44-55
5. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; I: 1273-5
6. Graham DY. Evolution of concepts regarding Helicobacter pylori: from a cause of gastritis to a public health problem [editorial]. Am J Gastroenterol 1994; 4: 469-72
7. Borody T, George L, Brandl S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991; 86: 1154-7
8. Forbes GM, Glaser ME, Cullen DJE, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994; 343: 258-60
9. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-27
10. National Institutes of Health. Consensus Conference. JAMA 1994; 272: 65-9
11. Paterson ML. Cost-benefit evaluation of a new technology for treatment of peptic ulcer disease. Manag Decis Econ 1983; 1: 50-62
12. Culver AJ, Maynard AK. Cost-effectiveness of duodenal ulcer treatment. Soc Sci Med 1981; 150: 3-11
13. Bell GD, Powell MB, Bolton G, et al. Clinical and pharmacoeconomic evaluation of management strategies for duodenal ulcer disease. Br J Med Econ 1993; 6: 45-58
14. Walan A, Eriksson S. Long term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. Scand J Gastroenterol 1994; 29 Suppl. 201: 91-7
15. Lind T, Veldhuyzen VJO, Unge P, et al. The mach 1 study: optimal one-week treatment for H. pylori defined [abstract]? Gut 1995; 37 Suppl. 1: A15
16. De Boer W, Driessen W, Jansz A, et al. Effect of acid suppression on the efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817-20
17. Arenas JI, Balanzó J, Berenguer J, et al. Consenso sobre Helicobacter pylori y patología gastroduodenal. Ann Med Intern 1994; 11: 304-6
18. Beck J, Pauker S. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-33
19. Labenz J, Gyenes E, Rülhl GH, et al. Amoxicillin plus ome-prazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomised, and controlled study. Gut 1993; 34: 1167-70
20. Burette A, Glupzynski Y, Deprez C, et al. Omeprazole + amoxicillin + clarithromycin therapy for H. pylori infection [abstract]. Gut 1995; 37 Suppl. 1: A353
21. Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994; 343: 508-10
22. 13C-urea breath test for detection of H. pylori. Eur J Gastroenterol Hepatol 1991; 3: 915-21
23. Cayla R, Zerbib A, De Mascarel A, et al. Terapia dual con atlas dosis de omeprazol frente a triple terapia con omeprazol en combinación con dos antibióticos para la eradicación de H. pylori: resultados de un estudio control de 100 pacientes. VIIth Symposium sobre Patología Gastroduodenal y H. pylori: Houston, 1994 Sept 30-Oct 1
24. Lamouliatte H, Cayla R, Zerbib F, et al. Triple therapy using proton pump inhibitor amoxicillin and clarithromycin for Helicobacter pylori eradication [abstract]. Gut 1995; 37 Suppl. 1: A91
25. Jones DB, Howden CW, Burgey DW, et al. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 1120-7
26. Humbert P, López P, Pardo A. La terapéutica de mantenimiento en la úlcera péptica. Medicina Integral 1994; 23: 248-59
27. Gisbert JP, Boixeda D, De Rafael L, et al. Efecto de la 'triple terapia' sobre la erradicación de H. pylori y la cicatrización de lu úlcera duodenal: estudio inicial y a los 6 meses. Rev Esp Enferm Dig 1995; 87: 193-8
28. Gustavson S, Holmberg L, Nyren O, et al. Risk of serious complications in patients with duodenal or prepyloric ulcers [abstract]. Gastroenterology 1990; 98 Suppl. 1: 54A
29. Cave DR. Enfoques terapéuticos en la enfermedad ulcerosa péptica recurrente. Hosp Pract 1993; 8: 31-42
30. Freston JW, Emerging strategies for managing peptic ulcer disease. Scand J Gastroenterol 1994; 29 Suppl. 201: 49-54
31. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90: 206-10
32. Encuesta de Morbilidad Hospitalaria. Madrid: Instituto National de Estadística, 1991
33. Generalitat Valenciana. Análisis comparativo por grupos decentros. Dirección General de Regimen Económico. Valencia: Servicio de Evaluación y Análisis Económico, 1995
34. García-Cardona F. La contabilidad de costes en Atención Primaria: cartera de servicios. Aten Primaria 1995; 15: 141-5
35. Catálogo de Especialidades Farmacéuticas. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos. 1995
36. Generalitat de Catalunya. Altas hospitalarias notificadas a Catalunya. Barcelona: Departament de Sanitat i Seguretat Social, 1992
37. Betolaza, JI. El coste por proceso en los hospitales de agudos de Osakidetza. Gac Sanit 1995; 48 Suppl.: 23-4
38. Alonso Cuesta, P. Análisis de la producció y dels costos en un hospital de malalts aguts. Barcelona: Generalitat de Catalunya, 1993
39. Sonnemberg A. Cost of medical and surgical treatment of duodenal ulcer. Gastroenterol 1989; 96: 1445-52
40. Ashton T. Cost-effectiveness of alternative medications in the treatment of duodenal ulcer. Scand J Gastroenterol 1991; 26: 82-8
41. Bell GD, Powell MB, Bolton G, et al. Clinical and pharmacoeconomic evaluation of management strategies for duodenal ulcer disease. Br J Med Econ 1993; 6: 45-58
42. Boixeda D, Martin de Argila C, Canton R, et al. Prevalencia de la infección por H. pylori en adultos sintomáticos. Rev Esp Enferm Dig 1994; 86: 569-76
43. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89 Suppl.: 116-28